ID   IDUA_HUMAN              Reviewed;         653 AA.
AC   P35475; B3KWK6;
DT   01-JUN-1994, integrated into UniProtKB/Swiss-Prot.
DT   04-APR-2006, sequence version 2.
DT   10-MAY-2017, entry version 164.
DE   RecName: Full=Alpha-L-iduronidase;
DE            EC=3.2.1.76;
DE   Flags: Precursor;
GN   Name=IDUA;
OS   Homo sapiens (Human).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC   Mammalia; Eutheria; Euarchontoglires; Primates; Haplorrhini;
OC   Catarrhini; Hominidae; Homo.
OX   NCBI_TaxID=9606;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 1), AND VARIANT GLN-33.
RC   TISSUE=Liver;
RX   PubMed=1946389; DOI=10.1073/pnas.88.21.9695;
RA   Scott H.S., Anson D.S., Orsborn A.M., Nelson P.V., Clements P.R.,
RA   Morris C.P., Hopwood J.J.;
RT   "Human alpha-L-iduronidase: cDNA isolation and expression.";
RL   Proc. Natl. Acad. Sci. U.S.A. 88:9695-9699(1991).
RN   [2]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA], AND VARIANT GLN-33.
RX   PubMed=1505961; DOI=10.1016/0888-7543(92)90053-U;
RA   Scott H.S., Guo X.H., Hopwood J.J., Morris C.P.;
RT   "Structure and sequence of the human alpha-L-iduronidase gene.";
RL   Genomics 13:1311-1313(1992).
RN   [3]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 2).
RX   PubMed=14702039; DOI=10.1038/ng1285;
RA   Ota T., Suzuki Y., Nishikawa T., Otsuki T., Sugiyama T., Irie R.,
RA   Wakamatsu A., Hayashi K., Sato H., Nagai K., Kimura K., Makita H.,
RA   Sekine M., Obayashi M., Nishi T., Shibahara T., Tanaka T., Ishii S.,
RA   Yamamoto J., Saito K., Kawai Y., Isono Y., Nakamura Y., Nagahari K.,
RA   Murakami K., Yasuda T., Iwayanagi T., Wagatsuma M., Shiratori A.,
RA   Sudo H., Hosoiri T., Kaku Y., Kodaira H., Kondo H., Sugawara M.,
RA   Takahashi M., Kanda K., Yokoi T., Furuya T., Kikkawa E., Omura Y.,
RA   Abe K., Kamihara K., Katsuta N., Sato K., Tanikawa M., Yamazaki M.,
RA   Ninomiya K., Ishibashi T., Yamashita H., Murakawa K., Fujimori K.,
RA   Tanai H., Kimata M., Watanabe M., Hiraoka S., Chiba Y., Ishida S.,
RA   Ono Y., Takiguchi S., Watanabe S., Yosida M., Hotuta T., Kusano J.,
RA   Kanehori K., Takahashi-Fujii A., Hara H., Tanase T.-O., Nomura Y.,
RA   Togiya S., Komai F., Hara R., Takeuchi K., Arita M., Imose N.,
RA   Musashino K., Yuuki H., Oshima A., Sasaki N., Aotsuka S.,
RA   Yoshikawa Y., Matsunawa H., Ichihara T., Shiohata N., Sano S.,
RA   Moriya S., Momiyama H., Satoh N., Takami S., Terashima Y., Suzuki O.,
RA   Nakagawa S., Senoh A., Mizoguchi H., Goto Y., Shimizu F., Wakebe H.,
RA   Hishigaki H., Watanabe T., Sugiyama A., Takemoto M., Kawakami B.,
RA   Yamazaki M., Watanabe K., Kumagai A., Itakura S., Fukuzumi Y.,
RA   Fujimori Y., Komiyama M., Tashiro H., Tanigami A., Fujiwara T.,
RA   Ono T., Yamada K., Fujii Y., Ozaki K., Hirao M., Ohmori Y.,
RA   Kawabata A., Hikiji T., Kobatake N., Inagaki H., Ikema Y., Okamoto S.,
RA   Okitani R., Kawakami T., Noguchi S., Itoh T., Shigeta K., Senba T.,
RA   Matsumura K., Nakajima Y., Mizuno T., Morinaga M., Sasaki M.,
RA   Togashi T., Oyama M., Hata H., Watanabe M., Komatsu T.,
RA   Mizushima-Sugano J., Satoh T., Shirai Y., Takahashi Y., Nakagawa K.,
RA   Okumura K., Nagase T., Nomura N., Kikuchi H., Masuho Y., Yamashita R.,
RA   Nakai K., Yada T., Nakamura Y., Ohara O., Isogai T., Sugano S.;
RT   "Complete sequencing and characterization of 21,243 full-length human
RT   cDNAs.";
RL   Nat. Genet. 36:40-45(2004).
RN   [4]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RX   PubMed=15815621; DOI=10.1038/nature03466;
RA   Hillier L.W., Graves T.A., Fulton R.S., Fulton L.A., Pepin K.H.,
RA   Minx P., Wagner-McPherson C., Layman D., Wylie K., Sekhon M.,
RA   Becker M.C., Fewell G.A., Delehaunty K.D., Miner T.L., Nash W.E.,
RA   Kremitzki C., Oddy L., Du H., Sun H., Bradshaw-Cordum H., Ali J.,
RA   Carter J., Cordes M., Harris A., Isak A., van Brunt A., Nguyen C.,
RA   Du F., Courtney L., Kalicki J., Ozersky P., Abbott S., Armstrong J.,
RA   Belter E.A., Caruso L., Cedroni M., Cotton M., Davidson T., Desai A.,
RA   Elliott G., Erb T., Fronick C., Gaige T., Haakenson W., Haglund K.,
RA   Holmes A., Harkins R., Kim K., Kruchowski S.S., Strong C.M.,
RA   Grewal N., Goyea E., Hou S., Levy A., Martinka S., Mead K.,
RA   McLellan M.D., Meyer R., Randall-Maher J., Tomlinson C.,
RA   Dauphin-Kohlberg S., Kozlowicz-Reilly A., Shah N.,
RA   Swearengen-Shahid S., Snider J., Strong J.T., Thompson J., Yoakum M.,
RA   Leonard S., Pearman C., Trani L., Radionenko M., Waligorski J.E.,
RA   Wang C., Rock S.M., Tin-Wollam A.-M., Maupin R., Latreille P.,
RA   Wendl M.C., Yang S.-P., Pohl C., Wallis J.W., Spieth J., Bieri T.A.,
RA   Berkowicz N., Nelson J.O., Osborne J., Ding L., Meyer R., Sabo A.,
RA   Shotland Y., Sinha P., Wohldmann P.E., Cook L.L., Hickenbotham M.T.,
RA   Eldred J., Williams D., Jones T.A., She X., Ciccarelli F.D.,
RA   Izaurralde E., Taylor J., Schmutz J., Myers R.M., Cox D.R., Huang X.,
RA   McPherson J.D., Mardis E.R., Clifton S.W., Warren W.C.,
RA   Chinwalla A.T., Eddy S.R., Marra M.A., Ovcharenko I., Furey T.S.,
RA   Miller W., Eichler E.E., Bork P., Suyama M., Torrents D.,
RA   Waterston R.H., Wilson R.K.;
RT   "Generation and annotation of the DNA sequences of human chromosomes 2
RT   and 4.";
RL   Nature 434:724-731(2005).
RN   [5]
RP   REVIEW ON VARIANTS.
RX   PubMed=8680403; DOI=10.1002/humu.1380060403;
RA   Scott H.S., Bunge S., Gal A., Clarke L.A., Morris C.P., Hopwood J.J.;
RT   "Molecular genetics of mucopolysaccharidosis type I: diagnostic,
RT   clinical, and biological implications.";
RL   Hum. Mutat. 6:288-302(1995).
RN   [6]
RP   GLYCOSYLATION [LARGE SCALE ANALYSIS] AT ASN-110.
RC   TISSUE=Liver;
RX   PubMed=19159218; DOI=10.1021/pr8008012;
RA   Chen R., Jiang X., Sun D., Han G., Wang F., Ye M., Wang L., Zou H.;
RT   "Glycoproteomics analysis of human liver tissue by combination of
RT   multiple enzyme digestion and hydrazide chemistry.";
RL   J. Proteome Res. 8:651-661(2009).
RN   [7]
RP   X-RAY CRYSTALLOGRAPHY (2.1 ANGSTROMS) OF 27-653 IN COMPLEX WITH
RP   IDURONATE ANALOGS, CATALYTIC ACTIVITY, ACTIVE SITE, CHARACTERIZATION
RP   OF VARIANT MPS1H ARG-533, DISULFIDE BOND, AND GLYCOSYLATION AT
RP   ASN-110; ASN-372 AND ASN-415.
RX   PubMed=24036510; DOI=10.1038/nchembio.1357;
RA   Bie H., Yin J., He X., Kermode A.R., Goddard-Borger E.D.,
RA   Withers S.G., James M.N.;
RT   "Insights into mucopolysaccharidosis I from the structure and action
RT   of alpha-L-iduronidase.";
RL   Nat. Chem. Biol. 9:739-745(2013).
RN   [8]
RP   X-RAY CRYSTALLOGRAPHY (2.3 ANGSTROMS) OF 27-653 IN COMPLEX WITH
RP   IDURONATE, CATALYTIC ACTIVITY, DISULFIDE BOND, SUBUNIT, GLYCOSYLATION
RP   AT ASN-110; ASN-372; ASN-415 AND ASN-451, AND IDENTIFICATION BY MASS
RP   SPECTROMETRY.
RX   PubMed=23959878; DOI=10.1073/pnas.1306939110;
RA   Maita N., Tsukimura T., Taniguchi T., Saito S., Ohno K., Taniguchi H.,
RA   Sakuraba H.;
RT   "Human alpha-L-iduronidase uses its own N-glycan as a substrate-
RT   binding and catalytic module.";
RL   Proc. Natl. Acad. Sci. U.S.A. 110:14628-14633(2013).
RN   [9]
RP   VARIANT MPS1H THR-75.
RX   PubMed=8019563; DOI=10.1002/humu.1380030316;
RA   Clarke L.A., Nelson P.V., Warrington C.L., Morris C.P., Hopwood J.J.,
RA   Scott H.S.;
RT   "Mutation analysis of 19 North American mucopolysaccharidosis type I
RT   patients: identification of two additional frequent mutations.";
RL   Hum. Mutat. 3:275-282(1994).
RN   [10]
RP   VARIANT MPS1H/S PRO-82.
RX   PubMed=8401515; DOI=10.1093/hmg/2.8.1311;
RA   Clark L.A., Scott H.S.;
RT   "Two novel mutations causing mucopolysaccharidosis type I detected by
RT   single strand conformational analysis of the alpha-L-iduronidase
RT   gene.";
RL   Hum. Mol. Genet. 2:1311-1312(1993).
RN   [11]
RP   VARIANT MPS1S GLN-89.
RX   PubMed=8213840;
RA   Scott H.S., Litjens T., Nelson P.V., Thompson P.R., Brooks D.A.,
RA   Hopwood J.J., Morris C.P.;
RT   "Identification of mutations in the alpha-L-iduronidase gene (IDUA)
RT   that cause Hurler and Scheie syndromes.";
RL   Am. J. Hum. Genet. 53:973-986(1993).
RN   [12]
RP   VARIANTS MPS1H PRO-366 AND ARG-409.
RX   PubMed=8328452;
RA   Bach G., Moskowitz S.M., Tieu P.T., Matynia A., Neufeld E.F.;
RT   "Molecular analysis of Hurler syndrome in Druze and Muslim Arab
RT   patients in Israel: multiple allelic mutations of the IDUA gene in a
RT   small geographic area.";
RL   Am. J. Hum. Genet. 53:330-338(1993).
RN   [13]
RP   VARIANT MPS1H ARG-533.
RX   PubMed=1301941; DOI=10.1002/humu.1380010412;
RA   Scott H.S., Litjens T., Nelson P.V., Brooks D.A., Hopwood J.J.,
RA   Morris C.P.;
RT   "Alpha-L-iduronidase mutations (Q70X and P533R) associate with a
RT   severe Hurler phenotype.";
RL   Hum. Mutat. 1:333-339(1992).
RN   [14]
RP   VARIANTS MPS1H ASP-51; THR-75; PRO-218; PRO-327; PRO-489 AND
RP   16-SER--ALA-19 DEL.
RX   PubMed=7951228; DOI=10.1093/hmg/3.6.861;
RA   Bunge S., Kleijer W.J., Steglich C., Beck M., Zuther C., Morris C.P.,
RA   Schwinger E., Hopwood J.J., Scott H.S., Gal A.;
RT   "Mucopolysaccharidosis type I: identification of 8 novel mutations and
RT   determination of the frequency of the two common alpha-L-iduronidase
RT   mutations (W402X and Q70X) among European patients.";
RL   Hum. Mol. Genet. 3:861-866(1994).
RN   [15]
RP   VARIANT GLN-33.
RX   PubMed=1362562; DOI=10.1007/BF00220095;
RA   Scott H.S., Litjens T., Hopwood J.J., Morris C.P.;
RT   "PCR detection of two RFLPs in exon I of the alpha-L-iduronidase
RT   (IDUA) gene.";
RL   Hum. Genet. 90:327-327(1992).
RN   [16]
RP   VARIANT THR-361.
RX   PubMed=8242073; DOI=10.1093/hmg/2.9.1471;
RA   Scott H.S., Nelson P.V., Litjens T., Hopwood J.J., Morris C.P.;
RT   "Multiple polymorphisms within the alpha-L-iduronidase gene (IDUA):
RT   implications for a role in modification of MPS-I disease phenotype.";
RL   Hum. Mol. Genet. 2:1471-1473(1993).
RN   [17]
RP   VARIANTS MPS1H/S PRO-490 AND LEU-496, AND VARIANT MPS1S PRO-492.
RX   PubMed=7550232; DOI=10.1002/humu.1380060111;
RA   Tieu P.T., Bach G., Matynia A., Hwang M., Neufeld E.F.;
RT   "Four novel mutations underlying mild or intermediate forms of alpha-
RT   L-iduronidase deficiency (MPS IS and MPS IH/S).";
RL   Hum. Mutat. 6:55-59(1995).
RN   [18]
RP   VARIANTS MPS1S TRP-89 AND HIS-383, VARIANT MPS1H 349-ASP-ASN-350 DEL,
RP   AND VARIANTS MPS1H/S THR-504 AND ARG-626.
RX   PubMed=7550242; DOI=10.1002/humu.1380060119;
RA   Bunge S., Kleijer W.J., Steglich C., Beck M., Schwinger E., Gal A.;
RT   "Mucopolysaccharidosis type I: identification of 13 novel mutations of
RT   the alpha-L-iduronidase gene.";
RL   Hum. Mutat. 6:91-94(1995).
RN   [19]
RP   VARIANT IDUA PSEUDODEFICIENCY THR-300.
RX   PubMed=8554071;
RA   Aronovich E.L., Pan D., Whitley C.B.;
RT   "Molecular genetic defect underlying alpha-L-iduronidase
RT   pseudodeficiency.";
RL   Am. J. Hum. Genet. 58:75-85(1996).
RN   [20]
RP   VARIANT MPS1H ARG-388.
RA   Bartholomew D.W., McClellan J.M.;
RT   "A novel missense mutation in the human IDUA gene associated with a
RT   severe Hurler's phenotype.";
RL   Hum. Mutat. 12:291-291(1998).
RN   [21]
RP   VARIANT MPS1H/S GLY-619.
RX   PubMed=10466419; DOI=10.1034/j.1399-0004.1999.560109.x;
RA   Lee-Chen G.J., Lin S.P., Tang Y.F., Chin Y.W.;
RT   "Mucopolysaccharidosis type I: characterization of novel mutations
RT   affecting alpha-L-iduronidase activity.";
RL   Clin. Genet. 56:66-70(1999).
RN   [22]
RP   VARIANT MPS1H/S ARG-346.
RX   PubMed=10735634; DOI=10.1034/j.1399-0004.2000.570207.x;
RA   Teng Y.N., Wang T.R., Hwu W.L., Lin S.P., Lee-Chen G.J.;
RT   "Identification and characterization of -3c-g acceptor splice site
RT   mutation in human alpha-L-iduronidase associated with
RT   mucopolysaccharidosis type IH/S.";
RL   Clin. Genet. 57:131-136(2000).
RN   [23]
RP   VARIANTS MPS1H ILE-133; LYS-182; ASP-208; TYR-349 AND ARG-533,
RP   VARIANTS MPS1H/S PHE-260; PRO-327; ARG-380 AND PRO-628, AND VARIANTS
RP   MPS1S GLN-89; ILE-350; HIS-383 AND ASP-445 DEL.
RX   PubMed=12559846; DOI=10.1016/S1096-7192(02)00200-7;
RA   Matte U., Yogalingam G., Brooks D., Leistner S., Schwartz I., Lima L.,
RA   Norato D.Y., Brum J.M., Beesley C., Winchester B., Giugliani R.,
RA   Hopwood J.J.;
RT   "Identification and characterization of 13 new mutations in
RT   mucopolysaccharidosis type I patients.";
RL   Mol. Genet. Metab. 78:37-43(2003).
RN   [24]
RP   VARIANTS MPS1H/S VAL-79; GLN-238; PRO-327; CYS-363; ARG-380; ARG-533
RP   AND ILE-602, VARIANT MPS1S ARG-423, VARIANTS GLN-82; GLN-105; THR-361
RP   AND ILE-454, CHARACTERIZATION OF VARIANTS MPS1H/S VAL-79; GLN-238;
RP   CYS-363 AND ILE-602, CHARACTERIZATION OF VARIANT MPS1S ARG-423, AND
RP   CHARACTERIZATION OF VARIANT GLN-82.
RX   PubMed=15300847; DOI=10.1002/humu.20081;
RA   Yogalingam G., Guo X.H., Muller V.J., Brooks D.A., Clements P.R.,
RA   Kakkis E.D., Hopwood J.J.;
RT   "Identification and molecular characterization of alpha-L-iduronidase
RT   mutations present in mucopolysaccharidosis type I patients undergoing
RT   enzyme replacement therapy.";
RL   Hum. Mutat. 24:199-207(2004).
RN   [25]
RP   VARIANTS MPS1H TYR-315; PRO-327 AND PHE-620, CHARACTERIZATION OF
RP   VARIANTS MPS1H TYR-315 AND PHE-620, VARIANT MPS1S ARG-380, AND
RP   VARIANTS GLN-33; GLN-105; THR-361 AND ILE-454.
RX   PubMed=19396826; DOI=10.1002/ajmg.a.32812;
RA   Vazna A., Beesley C., Berna L., Stolnaja L., Myskova H., Bouckova M.,
RA   Vlaskova H., Poupetova H., Zeman J., Magner M., Hlavata A.,
RA   Winchester B., Hrebicek M., Dvorakova L.;
RT   "Mucopolysaccharidosis type I in 21 Czech and Slovak patients:
RT   mutation analysis suggests a functional importance of C-terminus of
RT   the IDUA protein.";
RL   Am. J. Med. Genet. A 149A:965-974(2009).
RN   [26]
RP   VARIANTS MPS1H/S ARG-84; LYS-178; LEU-188; ARG-265; LYS-276; PRO-396;
RP   ARG-423; PRO-436; ARG-496; ARG-533 AND PHE-535, VARIANTS MPS1H ASP-51;
RP   PRO-103; PRO-327 AND ARG-385, VARIANTS MPS1S CYS-76; TRP-89; GLU-219;
RP   LYS-276; LEU-306; LYS-348; PRO-490 AND PRO-492, AND VARIANTS GLN-33;
RP   GLN-105; THR-361; ASN-449; ILE-454 AND THR-591.
RX   PubMed=21394825; DOI=10.1002/humu.21479;
RA   Bertola F., Filocamo M., Casati G., Mort M., Rosano C.,
RA   Tylki-Szymanska A., Tuysuz B., Gabrielli O., Grossi S., Scarpa M.,
RA   Parenti G., Antuzzi D., Dalmau J., Di Rocco M., Vici C.D., Okur I.,
RA   Rosell J., Rovelli A., Furlan F., Rigoldi M., Biondi A., Cooper D.N.,
RA   Parini R.;
RT   "IDUA mutational profiling of a cohort of 102 European patients with
RT   mucopolysaccharidosis type I: identification and characterization of
RT   35 novel alpha-L-iduronidase (IDUA) alleles.";
RL   Hum. Mutat. 32:E2189-E2210(2011).
RN   [27]
RP   VARIANT MPS1S PRO-18.
RX   PubMed=25256405; DOI=10.1111/cge.12507;
RA   Pasqualim G., Ribeiro M.G., da Fonseca G.G., Szlago M., Schenone A.,
RA   Lemes A., Rojas M.V., Matte U., Giugliani R.;
RT   "p.L18P: a novel IDUA mutation that causes a distinct attenuated
RT   phenotype in mucopolysaccharidosis type I patients.";
RL   Clin. Genet. 88:376-380(2015).
CC   -!- CATALYTIC ACTIVITY: Hydrolysis of unsulfated alpha-L-iduronosidic
CC       linkages in dermatan sulfate. {ECO:0000269|PubMed:23959878,
CC       ECO:0000269|PubMed:24036510}.
CC   -!- SUBUNIT: Monomer. {ECO:0000269|PubMed:23959878,
CC       ECO:0000269|PubMed:24036510}.
CC   -!- SUBCELLULAR LOCATION: Lysosome.
CC   -!- ALTERNATIVE PRODUCTS:
CC       Event=Alternative splicing; Named isoforms=2;
CC       Name=1;
CC         IsoId=P35475-1; Sequence=Displayed;
CC       Name=2;
CC         IsoId=P35475-2; Sequence=VSP_057029, VSP_057030;
CC         Note=No experimental confirmation available.;
CC   -!- TISSUE SPECIFICITY: Ubiquitous.
CC   -!- PTM: N-glycosylation at Asn-372 contributes to substrate binding
CC       and is required for full enzymatic activity.
CC       {ECO:0000269|PubMed:19159218, ECO:0000269|PubMed:23959878,
CC       ECO:0000269|PubMed:24036510}.
CC   -!- DISEASE: Mucopolysaccharidosis 1H (MPS1H) [MIM:607014]: A severe
CC       form of mucopolysaccharidosis type 1, a rare lysosomal storage
CC       disease characterized by progressive physical deterioration with
CC       urinary excretion of dermatan sulfate and heparan sulfate.
CC       Patients with MPS1H usually present, within the first year of
CC       life, a combination of hepatosplenomegaly, skeletal deformities,
CC       corneal clouding and severe mental retardation. Obstructive
CC       airways disease, respiratory infection and cardiac complications
CC       usually result in death before 10 years of age.
CC       {ECO:0000269|PubMed:10466419, ECO:0000269|PubMed:10735634,
CC       ECO:0000269|PubMed:12559846, ECO:0000269|PubMed:1301941,
CC       ECO:0000269|PubMed:15300847, ECO:0000269|PubMed:19396826,
CC       ECO:0000269|PubMed:21394825, ECO:0000269|PubMed:24036510,
CC       ECO:0000269|PubMed:7550232, ECO:0000269|PubMed:7550242,
CC       ECO:0000269|PubMed:7951228, ECO:0000269|PubMed:8019563,
CC       ECO:0000269|PubMed:8328452, ECO:0000269|PubMed:8401515,
CC       ECO:0000269|Ref.20}. Note=The disease is caused by mutations
CC       affecting the gene represented in this entry.
CC   -!- DISEASE: Mucopolysaccharidosis 1H/S (MPS1H/S) [MIM:607015]: A form
CC       of mucopolysaccharidosis type 1, a rare lysosomal storage disease
CC       characterized by progressive physical deterioration with urinary
CC       excretion of dermatan sulfate and heparan sulfate. MPS1H/S
CC       represents an intermediate phenotype of the MPS1 clinical
CC       spectrum. It is characterized by relatively little neurological
CC       involvement, but most of the somatic symptoms described for severe
CC       MPS1 develop in the early to mid-teens, causing considerable loss
CC       of mobility. {ECO:0000269|PubMed:10466419,
CC       ECO:0000269|PubMed:10735634, ECO:0000269|PubMed:12559846,
CC       ECO:0000269|PubMed:15300847, ECO:0000269|PubMed:21394825,
CC       ECO:0000269|PubMed:7550232, ECO:0000269|PubMed:7550242,
CC       ECO:0000269|PubMed:8401515}. Note=The disease is caused by
CC       mutations affecting the gene represented in this entry.
CC   -!- DISEASE: Mucopolysaccharidosis 1S (MPS1S) [MIM:607016]: A mild
CC       form of mucopolysaccharidosis type 1, a rare lysosomal storage
CC       disease characterized by progressive physical deterioration with
CC       urinary excretion of dermatan sulfate and heparan sulfate.
CC       Patients with MPS1S may have little or no neurological
CC       involvement, normal stature and life span, but present development
CC       of joints stiffness, mild hepatosplenomegaly, aortic valve disease
CC       and corneal clouding. {ECO:0000269|PubMed:12559846,
CC       ECO:0000269|PubMed:15300847, ECO:0000269|PubMed:19396826,
CC       ECO:0000269|PubMed:21394825, ECO:0000269|PubMed:25256405,
CC       ECO:0000269|PubMed:7550232, ECO:0000269|PubMed:7550242,
CC       ECO:0000269|PubMed:8213840}. Note=The disease is caused by
CC       mutations affecting the gene represented in this entry.
CC   -!- SIMILARITY: Belongs to the glycosyl hydrolase 39 family.
CC       {ECO:0000305}.
CC   -----------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see http://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution-NoDerivs License
CC   -----------------------------------------------------------------------
DR   EMBL; M74715; AAA81589.1; -; mRNA.
DR   EMBL; M95740; AAA51698.1; -; Genomic_DNA.
DR   EMBL; M95739; AAA51698.1; JOINED; Genomic_DNA.
DR   EMBL; AK125223; BAG54168.1; -; mRNA.
DR   EMBL; AC019103; -; NOT_ANNOTATED_CDS; Genomic_DNA.
DR   CCDS; CCDS3343.1; -. [P35475-1]
DR   PIR; S53645; S53645.
DR   RefSeq; NP_000194.2; NM_000203.4. [P35475-1]
DR   UniGene; Hs.89560; -.
DR   PDB; 1Y24; Model; -; A=36-522.
DR   PDB; 3W81; X-ray; 2.30 A; A/B=27-653.
DR   PDB; 3W82; X-ray; 2.76 A; A/B=27-653.
DR   PDB; 4KGJ; X-ray; 2.99 A; A/B=27-653.
DR   PDB; 4KGL; X-ray; 2.70 A; A/B=27-653.
DR   PDB; 4KH2; X-ray; 2.36 A; A/B=27-653.
DR   PDB; 4MJ2; X-ray; 2.10 A; A/B=1-653.
DR   PDB; 4MJ4; X-ray; 2.17 A; A=1-653.
DR   PDB; 4OBR; X-ray; 2.46 A; A/B=27-653.
DR   PDB; 4OBS; X-ray; 2.26 A; A=27-653.
DR   PDBsum; 1Y24; -.
DR   PDBsum; 3W81; -.
DR   PDBsum; 3W82; -.
DR   PDBsum; 4KGJ; -.
DR   PDBsum; 4KGL; -.
DR   PDBsum; 4KH2; -.
DR   PDBsum; 4MJ2; -.
DR   PDBsum; 4MJ4; -.
DR   PDBsum; 4OBR; -.
DR   PDBsum; 4OBS; -.
DR   ProteinModelPortal; P35475; -.
DR   SMR; P35475; -.
DR   BioGrid; 109651; 1.
DR   IntAct; P35475; 1.
DR   MINT; MINT-1397491; -.
DR   STRING; 9606.ENSP00000247933; -.
DR   CAZy; GH39; Glycoside Hydrolase Family 39.
DR   iPTMnet; P35475; -.
DR   PhosphoSitePlus; P35475; -.
DR   BioMuta; IDUA; -.
DR   DMDM; 92090608; -.
DR   EPD; P35475; -.
DR   MaxQB; P35475; -.
DR   PaxDb; P35475; -.
DR   PeptideAtlas; P35475; -.
DR   PRIDE; P35475; -.
DR   Ensembl; ENST00000247933; ENSP00000247933; ENSG00000127415. [P35475-1]
DR   GeneID; 3425; -.
DR   KEGG; hsa:3425; -.
DR   UCSC; uc003gby.5; human. [P35475-1]
DR   CTD; 3425; -.
DR   DisGeNET; 3425; -.
DR   GeneCards; IDUA; -.
DR   GeneReviews; IDUA; -.
DR   H-InvDB; HIX0200643; -.
DR   HGNC; HGNC:5391; IDUA.
DR   HPA; CAB025901; -.
DR   HPA; HPA046979; -.
DR   HPA; HPA054254; -.
DR   MalaCards; IDUA; -.
DR   MIM; 252800; gene.
DR   MIM; 607014; phenotype.
DR   MIM; 607015; phenotype.
DR   MIM; 607016; phenotype.
DR   neXtProt; NX_P35475; -.
DR   OpenTargets; ENSG00000127415; -.
DR   Orphanet; 93473; Hurler syndrome.
DR   Orphanet; 93476; Hurler-Scheie syndrome.
DR   Orphanet; 93474; Scheie syndrome.
DR   PharmGKB; PA29638; -.
DR   eggNOG; ENOG410IEET; Eukaryota.
DR   eggNOG; ENOG410XWW3; LUCA.
DR   GeneTree; ENSGT00390000015494; -.
DR   HOGENOM; HOG000007042; -.
DR   HOVERGEN; HBG006121; -.
DR   InParanoid; P35475; -.
DR   KO; K01217; -.
DR   OMA; IANESAF; -.
DR   OrthoDB; EOG091G0N7H; -.
DR   PhylomeDB; P35475; -.
DR   TreeFam; TF323228; -.
DR   BioCyc; MetaCyc:HS05096-MONOMER; -.
DR   BRENDA; 3.2.1.76; 2681.
DR   Reactome; R-HSA-2024096; HS-GAG degradation.
DR   Reactome; R-HSA-2024101; CS/DS degradation.
DR   SABIO-RK; P35475; -.
DR   ChiTaRS; IDUA; human.
DR   GenomeRNAi; 3425; -.
DR   PRO; PR:P35475; -.
DR   Proteomes; UP000005640; Chromosome 4.
DR   Bgee; ENSG00000127415; -.
DR   CleanEx; HS_IDUA; -.
DR   ExpressionAtlas; P35475; baseline and differential.
DR   Genevisible; P35475; HS.
DR   GO; GO:0030135; C:coated vesicle; IEA:Ensembl.
DR   GO; GO:0070062; C:extracellular exosome; IDA:UniProtKB.
DR   GO; GO:0043202; C:lysosomal lumen; TAS:Reactome.
DR   GO; GO:0003940; F:L-iduronidase activity; IDA:UniProtKB.
DR   GO; GO:0005102; F:receptor binding; IEA:Ensembl.
DR   GO; GO:0030207; P:chondroitin sulfate catabolic process; TAS:Reactome.
DR   GO; GO:0030209; P:dermatan sulfate catabolic process; IDA:UniProtKB.
DR   GO; GO:0005984; P:disaccharide metabolic process; TAS:ProtInc.
DR   GO; GO:0006027; P:glycosaminoglycan catabolic process; TAS:Reactome.
DR   Gene3D; 2.60.40.10; -; 1.
DR   InterPro; IPR000514; Glyco_hydro_39.
DR   InterPro; IPR017853; Glycoside_hydrolase_SF.
DR   InterPro; IPR013783; Ig-like_fold.
DR   Pfam; PF01229; Glyco_hydro_39; 1.
DR   PRINTS; PR00745; GLHYDRLASE39.
DR   SUPFAM; SSF51445; SSF51445; 1.
DR   PROSITE; PS01027; GLYCOSYL_HYDROL_F39; 1.
PE   1: Evidence at protein level;
KW   3D-structure; Alternative splicing; Complete proteome;
KW   Disease mutation; Disulfide bond; Glycoprotein; Glycosidase;
KW   Hydrolase; Lysosome; Mucopolysaccharidosis; Polymorphism;
KW   Reference proteome; Signal.
FT   SIGNAL        1     27       {ECO:0000255}.
FT   CHAIN        28    653       Alpha-L-iduronidase.
FT                                /FTId=PRO_0000012200.
FT   REGION      305    306       Substrate binding.
FT   ACT_SITE    182    182       Proton donor. {ECO:0000255|PROSITE-
FT                                ProRule:PRU10068,
FT                                ECO:0000269|PubMed:24036510}.
FT   ACT_SITE    299    299       Nucleophile.
FT                                {ECO:0000269|PubMed:24036510}.
FT   BINDING      91     91       Substrate.
FT   BINDING     181    181       Substrate.
FT   BINDING     264    264       Substrate.
FT   BINDING     349    349       Substrate.
FT   BINDING     363    363       Substrate.
FT   CARBOHYD    110    110       N-linked (GlcNAc...) asparagine.
FT                                {ECO:0000269|PubMed:19159218,
FT                                ECO:0000269|PubMed:23959878,
FT                                ECO:0000269|PubMed:24036510}.
FT   CARBOHYD    190    190       N-linked (GlcNAc...) asparagine.
FT                                {ECO:0000255}.
FT   CARBOHYD    336    336       N-linked (GlcNAc...) asparagine.
FT                                {ECO:0000255}.
FT   CARBOHYD    372    372       N-linked (GlcNAc...) asparagine.
FT                                {ECO:0000269|PubMed:23959878,
FT                                ECO:0000269|PubMed:24036510}.
FT   CARBOHYD    415    415       N-linked (GlcNAc...) asparagine.
FT                                {ECO:0000269|PubMed:23959878,
FT                                ECO:0000269|PubMed:24036510}.
FT   CARBOHYD    451    451       N-linked (GlcNAc...) asparagine.
FT                                {ECO:0000269|PubMed:23959878}.
FT   DISULFID    541    577       {ECO:0000269|PubMed:23959878,
FT                                ECO:0000269|PubMed:24036510}.
FT   VAR_SEQ      53    100       CPPLPHSQADQYVLSWDQQLNLAYVGAVPHRGIKQVRTHWL
FT                                LELVTTR -> W (in isoform 2).
FT                                {ECO:0000303|PubMed:14702039}.
FT                                /FTId=VSP_057029.
FT   VAR_SEQ     265    324       GARSSISILEQEKVVAQQIRQLFPKFADTPIYNDEADPLVG
FT                                WSLPQPWRADVTYAAMVVK -> VRPAPPSAPVFCALSRCA
FT                                PGRADPGGAEAAPPAGCAQLHLHPGAGEGRRAADPAALPQV
FT                                RGHPHLQRRGGPAGGLVPATAVEGGRDLRGHGGEGGPAQRP
FT                                ARPPATFLPRRDRRAVAAPPGPSCPGHPQ (in isoform
FT                                2). {ECO:0000303|PubMed:14702039}.
FT                                /FTId=VSP_057030.
FT   VARIANT      16     19       Missing (in MPS1H).
FT                                {ECO:0000269|PubMed:7951228}.
FT                                /FTId=VAR_003349.
FT   VARIANT      18     18       L -> P (in MPS1S; dbSNP:rs794726878).
FT                                {ECO:0000269|PubMed:25256405}.
FT                                /FTId=VAR_072367.
FT   VARIANT      33     33       H -> Q (in dbSNP:rs10794537).
FT                                {ECO:0000269|PubMed:1362562,
FT                                ECO:0000269|PubMed:1505961,
FT                                ECO:0000269|PubMed:19396826,
FT                                ECO:0000269|PubMed:1946389,
FT                                ECO:0000269|PubMed:21394825}.
FT                                /FTId=VAR_003350.
FT   VARIANT      51     51       G -> D (in MPS1H; dbSNP:rs794726877).
FT                                {ECO:0000269|PubMed:21394825,
FT                                ECO:0000269|PubMed:7951228}.
FT                                /FTId=VAR_003351.
FT   VARIANT      75     75       A -> T (in MPS1H; dbSNP:rs758452450).
FT                                {ECO:0000269|PubMed:7951228,
FT                                ECO:0000269|PubMed:8019563}.
FT                                /FTId=VAR_003352.
FT   VARIANT      76     76       Y -> C (in MPS1S; dbSNP:rs780165694).
FT                                {ECO:0000269|PubMed:21394825}.
FT                                /FTId=VAR_066215.
FT   VARIANT      79     79       A -> V (in MPS1H/S; reduction of activity
FT                                and protein levels; dbSNP:rs747981483).
FT                                {ECO:0000269|PubMed:15300847}.
FT                                /FTId=VAR_020975.
FT   VARIANT      82     82       H -> P (in MPS1H/S; dbSNP:rs794727239).
FT                                {ECO:0000269|PubMed:8401515}.
FT                                /FTId=VAR_003353.
FT   VARIANT      82     82       H -> Q (reduction of protein levels;
FT                                dbSNP:rs148775298).
FT                                {ECO:0000269|PubMed:15300847}.
FT                                /FTId=VAR_020976.
FT   VARIANT      84     84       G -> R (in MPS1H/S).
FT                                {ECO:0000269|PubMed:21394825}.
FT                                /FTId=VAR_066216.
FT   VARIANT      89     89       R -> Q (in MPS1S; dbSNP:rs121965029).
FT                                {ECO:0000269|PubMed:12559846,
FT                                ECO:0000269|PubMed:8213840}.
FT                                /FTId=VAR_003354.
FT   VARIANT      89     89       R -> W (in MPS1S; dbSNP:rs754966840).
FT                                {ECO:0000269|PubMed:21394825,
FT                                ECO:0000269|PubMed:7550242}.
FT                                /FTId=VAR_003355.
FT   VARIANT     103    103       T -> P (in MPS1H; uncertain pathological
FT                                role). {ECO:0000269|PubMed:21394825}.
FT                                /FTId=VAR_066217.
FT   VARIANT     105    105       R -> Q (in dbSNP:rs3755955).
FT                                {ECO:0000269|PubMed:15300847,
FT                                ECO:0000269|PubMed:19396826,
FT                                ECO:0000269|PubMed:21394825}.
FT                                /FTId=VAR_003356.
FT   VARIANT     116    116       G -> R (in dbSNP:rs148946496).
FT                                /FTId=VAR_003357.
FT   VARIANT     133    133       M -> I (in MPS1H; dbSNP:rs558683362).
FT                                {ECO:0000269|PubMed:12559846}.
FT                                /FTId=VAR_020977.
FT   VARIANT     178    178       E -> K (in MPS1H/S).
FT                                {ECO:0000269|PubMed:21394825}.
FT                                /FTId=VAR_066218.
FT   VARIANT     182    182       E -> K (in MPS1H; dbSNP:rs754154200).
FT                                {ECO:0000269|PubMed:12559846}.
FT                                /FTId=VAR_020978.
FT   VARIANT     188    188       F -> L (in MPS1H/S; associated with R-
FT                                423). {ECO:0000269|PubMed:21394825}.
FT                                /FTId=VAR_066219.
FT   VARIANT     208    208       G -> D (in MPS1H).
FT                                {ECO:0000269|PubMed:12559846}.
FT                                /FTId=VAR_020979.
FT   VARIANT     218    218       L -> P (in MPS1H; dbSNP:rs869025584).
FT                                {ECO:0000269|PubMed:7951228}.
FT                                /FTId=VAR_003358.
FT   VARIANT     219    219       G -> E (in MPS1S).
FT                                {ECO:0000269|PubMed:21394825}.
FT                                /FTId=VAR_066220.
FT   VARIANT     238    238       L -> Q (in MPS1H/S; dbSNP:rs148789453).
FT                                {ECO:0000269|PubMed:15300847}.
FT                                /FTId=VAR_020980.
FT   VARIANT     260    260       S -> F (in MPS1H/S).
FT                                {ECO:0000269|PubMed:12559846}.
FT                                /FTId=VAR_020981.
FT   VARIANT     265    265       G -> R (in MPS1H/S; dbSNP:rs369090960).
FT                                {ECO:0000269|PubMed:21394825}.
FT                                /FTId=VAR_066221.
FT   VARIANT     276    276       E -> K (in MPS1H/S and MPS1S).
FT                                {ECO:0000269|PubMed:21394825}.
FT                                /FTId=VAR_066222.
FT   VARIANT     279    279       V -> A.
FT                                /FTId=VAR_003359.
FT   VARIANT     300    300       A -> T (in IDUA pseudodeficiency;
FT                                dbSNP:rs121965030).
FT                                {ECO:0000269|PubMed:8554071}.
FT                                /FTId=VAR_017435.
FT   VARIANT     306    306       W -> L (in MPS1S).
FT                                {ECO:0000269|PubMed:21394825}.
FT                                /FTId=VAR_066223.
FT   VARIANT     315    315       D -> Y (in MPS1H; loss of function;
FT                                undetectable enzyme activity).
FT                                {ECO:0000269|PubMed:19396826}.
FT                                /FTId=VAR_003360.
FT   VARIANT     327    327       A -> P (in MPS1H; MPS1H/S;
FT                                dbSNP:rs199801029).
FT                                {ECO:0000269|PubMed:12559846,
FT                                ECO:0000269|PubMed:15300847,
FT                                ECO:0000269|PubMed:19396826,
FT                                ECO:0000269|PubMed:21394825,
FT                                ECO:0000269|PubMed:7951228}.
FT                                /FTId=VAR_003361.
FT   VARIANT     346    346       L -> R (in MPS1H/S; 0.4% of normal
FT                                activity; dbSNP:rs121965033).
FT                                {ECO:0000269|PubMed:10735634}.
FT                                /FTId=VAR_017436.
FT   VARIANT     348    348       N -> K (in MPS1S; dbSNP:rs746766617).
FT                                {ECO:0000269|PubMed:21394825}.
FT                                /FTId=VAR_066224.
FT   VARIANT     349    350       Missing (in MPS1H).
FT                                {ECO:0000269|PubMed:7550242}.
FT                                /FTId=VAR_003363.
FT   VARIANT     349    349       D -> N (in MPS1H; dbSNP:rs368454909).
FT                                /FTId=VAR_003362.
FT   VARIANT     349    349       D -> Y (in MPS1H).
FT                                {ECO:0000269|PubMed:12559846}.
FT                                /FTId=VAR_020982.
FT   VARIANT     350    350       N -> I (in MPS1S).
FT                                {ECO:0000269|PubMed:12559846}.
FT                                /FTId=VAR_020983.
FT   VARIANT     361    361       A -> T (in dbSNP:rs6831280).
FT                                {ECO:0000269|PubMed:15300847,
FT                                ECO:0000269|PubMed:19396826,
FT                                ECO:0000269|PubMed:21394825,
FT                                ECO:0000269|PubMed:8242073}.
FT                                /FTId=VAR_003364.
FT   VARIANT     363    363       R -> C (in MPS1H/S; loss of activity;
FT                                dbSNP:rs750496798).
FT                                {ECO:0000269|PubMed:15300847}.
FT                                /FTId=VAR_020984.
FT   VARIANT     366    366       T -> P (in MPS1H; dbSNP:rs121965024).
FT                                {ECO:0000269|PubMed:8328452}.
FT                                /FTId=VAR_003365.
FT   VARIANT     380    380       Q -> R (in MPS1H/S and MPS1S;
FT                                dbSNP:rs762903007).
FT                                {ECO:0000269|PubMed:12559846,
FT                                ECO:0000269|PubMed:15300847,
FT                                ECO:0000269|PubMed:19396826}.
FT                                /FTId=VAR_003366.
FT   VARIANT     383    383       R -> H (in MPS1S; 2-3% of normal
FT                                activity; dbSNP:rs754949360).
FT                                {ECO:0000269|PubMed:12559846,
FT                                ECO:0000269|PubMed:7550242}.
FT                                /FTId=VAR_003367.
FT   VARIANT     385    385       P -> R (in MPS1H).
FT                                {ECO:0000269|PubMed:21394825}.
FT                                /FTId=VAR_066225.
FT   VARIANT     388    388       T -> R (in MPS1H). {ECO:0000269|Ref.20}.
FT                                /FTId=VAR_003368.
FT   VARIANT     396    396       L -> LALL (in MPS1H).
FT                                /FTId=VAR_003369.
FT   VARIANT     396    396       L -> P (in MPS1H/S).
FT                                {ECO:0000269|PubMed:21394825}.
FT                                /FTId=VAR_066226.
FT   VARIANT     409    409       G -> R (in MPS1H; dbSNP:rs11934801).
FT                                {ECO:0000269|PubMed:8328452}.
FT                                /FTId=VAR_003370.
FT   VARIANT     423    423       S -> R (in MPS1S and MPS1H/S; associated
FT                                with L-188 in a patient with MPS1H/S;
FT                                significant reduction of activity and
FT                                protein levels).
FT                                {ECO:0000269|PubMed:15300847,
FT                                ECO:0000269|PubMed:21394825}.
FT                                /FTId=VAR_020985.
FT   VARIANT     436    436       A -> P (in MPS1H/S).
FT                                {ECO:0000269|PubMed:21394825}.
FT                                /FTId=VAR_066227.
FT   VARIANT     445    445       Missing (in MPS1S).
FT                                {ECO:0000269|PubMed:12559846}.
FT                                /FTId=VAR_003371.
FT   VARIANT     449    449       H -> N (in dbSNP:rs532731688).
FT                                {ECO:0000269|PubMed:21394825}.
FT                                /FTId=VAR_066228.
FT   VARIANT     454    454       V -> I (in dbSNP:rs73066479).
FT                                {ECO:0000269|PubMed:15300847,
FT                                ECO:0000269|PubMed:19396826,
FT                                ECO:0000269|PubMed:21394825}.
FT                                /FTId=VAR_003372.
FT   VARIANT     489    489       R -> P (in MPS1H; dbSNP:rs4690226).
FT                                {ECO:0000269|PubMed:7951228}.
FT                                /FTId=VAR_003373.
FT   VARIANT     490    490       L -> P (in MPS1H/S and MPS1S;
FT                                dbSNP:rs121965027).
FT                                {ECO:0000269|PubMed:21394825,
FT                                ECO:0000269|PubMed:7550232}.
FT                                /FTId=VAR_003374.
FT   VARIANT     492    492       R -> P (in MPS1S; dbSNP:rs121965026).
FT                                {ECO:0000269|PubMed:21394825,
FT                                ECO:0000269|PubMed:7550232}.
FT                                /FTId=VAR_003375.
FT   VARIANT     496    496       P -> L (in MPS1H/S).
FT                                {ECO:0000269|PubMed:7550232}.
FT                                /FTId=VAR_003376.
FT   VARIANT     496    496       P -> R (in MPS1H/S; dbSNP:rs772416503).
FT                                {ECO:0000269|PubMed:21394825}.
FT                                /FTId=VAR_066229.
FT   VARIANT     504    504       M -> T (in MPS1H/S).
FT                                {ECO:0000269|PubMed:7550242}.
FT                                /FTId=VAR_003377.
FT   VARIANT     533    533       P -> R (in MPS1H and MPS1H/S; in 3% of
FT                                the MPS1H patients; reduces catalytic
FT                                activity and protein stability;
FT                                dbSNP:rs121965021).
FT                                {ECO:0000269|PubMed:12559846,
FT                                ECO:0000269|PubMed:1301941,
FT                                ECO:0000269|PubMed:15300847,
FT                                ECO:0000269|PubMed:21394825,
FT                                ECO:0000269|PubMed:24036510}.
FT                                /FTId=VAR_003378.
FT   VARIANT     535    535       L -> F (in MPS1H/S).
FT                                {ECO:0000269|PubMed:21394825}.
FT                                /FTId=VAR_066230.
FT   VARIANT     591    591       A -> T (in dbSNP:rs398123257).
FT                                {ECO:0000269|PubMed:21394825}.
FT                                /FTId=VAR_066231.
FT   VARIANT     602    602       F -> I (in MPS1H/S; reduction of activity
FT                                and protein levels).
FT                                {ECO:0000269|PubMed:15300847}.
FT                                /FTId=VAR_020986.
FT   VARIANT     619    619       R -> G (in MPS1H/S; 1.5% of normal
FT                                activity; dbSNP:rs121965031).
FT                                {ECO:0000269|PubMed:10466419}.
FT                                /FTId=VAR_017437.
FT   VARIANT     620    620       V -> F (in MPS1H; loss of function;
FT                                undetectable enzyme activity).
FT                                {ECO:0000269|PubMed:19396826}.
FT                                /FTId=VAR_072368.
FT   VARIANT     626    626       W -> R (in MPS1H/S).
FT                                {ECO:0000269|PubMed:7550242}.
FT                                /FTId=VAR_003379.
FT   VARIANT     628    628       R -> P (in MPS1H/S; dbSNP:rs200448421).
FT                                {ECO:0000269|PubMed:12559846}.
FT                                /FTId=VAR_020987.
FT   CONFLICT    622    622       A -> T (in Ref. 2; AAA51698).
FT                                {ECO:0000305}.
FT   STRAND       30     42       {ECO:0000244|PDB:4MJ2}.
FT   STRAND       49     52       {ECO:0000244|PDB:4MJ2}.
FT   HELIX        58     60       {ECO:0000244|PDB:3W81}.
FT   HELIX        64     66       {ECO:0000244|PDB:4MJ4}.
FT   HELIX        68     78       {ECO:0000244|PDB:4MJ2}.
FT   HELIX        81     83       {ECO:0000244|PDB:4MJ2}.
FT   STRAND       87     90       {ECO:0000244|PDB:4MJ2}.
FT   HELIX        93     95       {ECO:0000244|PDB:4MJ2}.
FT   STRAND       98    100       {ECO:0000244|PDB:4MJ4}.
FT   TURN        103    105       {ECO:0000244|PDB:3W81}.
FT   STRAND      108    110       {ECO:0000244|PDB:4MJ4}.
FT   HELIX       112    123       {ECO:0000244|PDB:4MJ2}.
FT   STRAND      127    131       {ECO:0000244|PDB:4MJ2}.
FT   TURN        136    139       {ECO:0000244|PDB:4MJ2}.
FT   STRAND      142    144       {ECO:0000244|PDB:4KGJ}.
FT   HELIX       146    167       {ECO:0000244|PDB:4MJ2}.
FT   HELIX       169    172       {ECO:0000244|PDB:4MJ2}.
FT   STRAND      176    178       {ECO:0000244|PDB:4MJ2}.
FT   HELIX       183    185       {ECO:0000244|PDB:4MJ2}.
FT   HELIX       195    212       {ECO:0000244|PDB:4MJ2}.
FT   STRAND      217    223       {ECO:0000244|PDB:4MJ2}.
FT   HELIX       232    243       {ECO:0000244|PDB:4MJ2}.
FT   TURN        247    249       {ECO:0000244|PDB:4MJ2}.
FT   STRAND      257    261       {ECO:0000244|PDB:4MJ2}.
FT   HELIX       269    286       {ECO:0000244|PDB:4MJ2}.
FT   HELIX       288    290       {ECO:0000244|PDB:4MJ2}.
FT   STRAND      295    298       {ECO:0000244|PDB:4MJ2}.
FT   STRAND      302    304       {ECO:0000244|PDB:4MJ2}.
FT   STRAND      306    308       {ECO:0000244|PDB:4KGL}.
FT   HELIX       311    314       {ECO:0000244|PDB:4MJ2}.
FT   HELIX       316    332       {ECO:0000244|PDB:4MJ2}.
FT   STRAND      334    336       {ECO:0000244|PDB:4KGJ}.
FT   STRAND      343    346       {ECO:0000244|PDB:4MJ2}.
FT   TURN        359    361       {ECO:0000244|PDB:4MJ2}.
FT   STRAND      362    371       {ECO:0000244|PDB:4MJ2}.
FT   STRAND      374    376       {ECO:0000244|PDB:4MJ2}.
FT   STRAND      378    383       {ECO:0000244|PDB:4MJ2}.
FT   HELIX       385    393       {ECO:0000244|PDB:4MJ2}.
FT   STRAND      398    407       {ECO:0000244|PDB:4MJ2}.
FT   STRAND      410    412       {ECO:0000244|PDB:4MJ2}.
FT   STRAND      414    425       {ECO:0000244|PDB:4MJ2}.
FT   STRAND      429    431       {ECO:0000244|PDB:4KGL}.
FT   STRAND      435    442       {ECO:0000244|PDB:4MJ2}.
FT   STRAND      449    461       {ECO:0000244|PDB:4MJ2}.
FT   STRAND      470    477       {ECO:0000244|PDB:4MJ2}.
FT   TURN        478    480       {ECO:0000244|PDB:4MJ2}.
FT   HELIX       483    489       {ECO:0000244|PDB:4MJ2}.
FT   HELIX       498    505       {ECO:0000244|PDB:4MJ2}.
FT   STRAND      511    517       {ECO:0000244|PDB:3W81}.
FT   TURN        520    522       {ECO:0000244|PDB:4MJ2}.
FT   STRAND      524    526       {ECO:0000244|PDB:4MJ2}.
FT   STRAND      529    541       {ECO:0000244|PDB:4MJ2}.
FT   STRAND      552    560       {ECO:0000244|PDB:4MJ2}.
FT   STRAND      563    569       {ECO:0000244|PDB:4MJ2}.
FT   TURN        571    573       {ECO:0000244|PDB:4OBS}.
FT   STRAND      578    586       {ECO:0000244|PDB:4MJ2}.
FT   STRAND      602    607       {ECO:0000244|PDB:4MJ2}.
FT   STRAND      616    624       {ECO:0000244|PDB:4MJ2}.
FT   STRAND      636    638       {ECO:0000244|PDB:4MJ2}.
SQ   SEQUENCE   653 AA;  72670 MW;  9D2399B22FD172BD CRC64;
     MRPLRPRAAL LALLASLLAA PPVAPAEAPH LVHVDAARAL WPLRRFWRST GFCPPLPHSQ
     ADQYVLSWDQ QLNLAYVGAV PHRGIKQVRT HWLLELVTTR GSTGRGLSYN FTHLDGYLDL
     LRENQLLPGF ELMGSASGHF TDFEDKQQVF EWKDLVSSLA RRYIGRYGLA HVSKWNFETW
     NEPDHHDFDN VSMTMQGFLN YYDACSEGLR AASPALRLGG PGDSFHTPPR SPLSWGLLRH
     CHDGTNFFTG EAGVRLDYIS LHRKGARSSI SILEQEKVVA QQIRQLFPKF ADTPIYNDEA
     DPLVGWSLPQ PWRADVTYAA MVVKVIAQHQ NLLLANTTSA FPYALLSNDN AFLSYHPHPF
     AQRTLTARFQ VNNTRPPHVQ LLRKPVLTAM GLLALLDEEQ LWAEVSQAGT VLDSNHTVGV
     LASAHRPQGP ADAWRAAVLI YASDDTRAHP NRSVAVTLRL RGVPPGPGLV YVTRYLDNGL
     CSPDGEWRRL GRPVFPTAEQ FRRMRAAEDP VAAAPRPLPA GGRLTLRPAL RLPSLLLVHV
     CARPEKPPGQ VTRLRALPLT QGQLVLVWSD EHVGSKCLWT YEIQFSQDGK AYTPVSRKPS
     TFNLFVFSPD TGAVSGSYRV RALDYWARPG PFSDPVPYLE VPVPRGPPSP GNP
//
